Equities research analysts at UBS Group initiated coverage on shares of Janux Therapeutics (NASDAQ:JANX – Get Free Report) in a report released on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $69.00 price target on the stock. UBS Group’s price objective suggests a potential upside of 29.43% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. Stifel Nicolaus initiated coverage on Janux Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $70.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a report on Monday, August 19th. Scotiabank cut their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Wedbush reaffirmed an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.44.
Get Our Latest Research Report on JANX
Janux Therapeutics Trading Up 3.0 %
Shares of JANX stock traded up $1.56 during trading hours on Thursday, hitting $53.31. 596,903 shares of the company were exchanged, compared to its average volume of 714,851. The company has a market capitalization of $2.76 billion, a PE ratio of -43.54 and a beta of 3.54. Janux Therapeutics has a 52 week low of $5.65 and a 52 week high of $65.60. The business has a 50 day moving average of $46.62 and a two-hundred day moving average of $45.79.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The business’s revenue for the quarter was up 709.1% on a year-over-year basis. On average, research analysts forecast that Janux Therapeutics will post -1.18 EPS for the current year.
Insider Transactions at Janux Therapeutics
In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the completion of the transaction, the insider now owns 3,162,851 shares in the company, valued at approximately $132,839,742. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the sale, the insider now owns 3,162,851 shares in the company, valued at approximately $132,839,742. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00. Following the sale, the chief executive officer now directly owns 307,054 shares of the company’s stock, valued at $14,219,670.74. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 395,610 shares of company stock worth $17,950,166 in the last ninety days. Insiders own 35.40% of the company’s stock.
Institutional Trading of Janux Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of JANX. Mirae Asset Global Investments Co. Ltd. raised its holdings in Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after acquiring an additional 339 shares during the period. Amalgamated Bank increased its stake in shares of Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the period. Summit Securities Group LLC bought a new position in shares of Janux Therapeutics during the second quarter worth approximately $29,000. Plato Investment Management Ltd acquired a new stake in Janux Therapeutics during the 2nd quarter worth approximately $42,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Janux Therapeutics in the 2nd quarter valued at $151,000. Institutional investors own 75.39% of the company’s stock.
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Recommended Stories
- Five stocks we like better than Janux Therapeutics
- Manufacturing Stocks Investing
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- 3 Warren Buffett Stocks to Buy Now
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Invest in the FAANG Stocks
- Tesla Stock: Buy the Dips, Sell the Rips
Should you invest $1,000 in Janux Therapeutics right now?
Before you consider Janux Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Janux Therapeutics wasn’t on the list.
While Janux Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
